TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27647120

Group type: EXPERIMENTAL
Intervention: Medial rectus muscle pulley fixation (pulley group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Augmented medial rectus muscle recession (augmented group)
Number of subjects: 60
Study: 27129009

Group type: EXPERIMENTAL
Intervention: ASP2151 (100, 200, or 400 mg daily for 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASP2151 (1,200 mg as a single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily for 3 days)
Number of subjects: 0
Study: 22389220

Group type: EXPERIMENTAL
Intervention: Highly efficient face mask
Number of subjects: 98

Group type: COMPARATOR
Intervention: No mask (control)
Number of subjects: 98
Study: 18214702

Group type: EXPERIMENTAL
Intervention: Simulation-based teaching (SBT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Problem-based discussion (PBD)
Number of subjects: 33
Study: 17179772

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal single-dose cream (CVSDC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Metronidazole vaginal gel (MVG)
Number of subjects: 55
Study: 15159307

Group type: EXPERIMENTAL
Intervention: Homozygous for the T allele at position -509
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Homozygous for the C allele at position +29
Number of subjects: 492

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 492
Study: 12428241

Group type: EXPERIMENTAL
Intervention: High-Dose D-Penicillamine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Low-Dose D-Penicillamine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Prednisone use at entry
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Skin scores
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: SRC
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Overall survival after SRC
Number of subjects: 134
Study: 9839295

Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: amlodipine 5 mg
Number of subjects: 48
Study: 8209936

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 492

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 492
Study: 2492170

Group type: EXPERIMENTAL
Intervention: Oral morphine solution (0.8 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31085282

Group type: EXPERIMENTAL
Intervention: Upper limb treatment based on voluntary task‐oriented movements
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive mobilization of shoulder, elbow, wrist and fingers (Control)
Number of subjects: 30
Study: 28295516

Group type: EXPERIMENTAL
Intervention: 2.5% BPO gel
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: 5% BPO gel
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 26268495

Group type: EXPERIMENTAL
Intervention: CPAP therapy combined with metoprolol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 56
Study: 23696477

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Programme (ERP)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 91
Study: 21718338

Group type: EXPERIMENTAL
Intervention: 0.28 water/powder ratio of white MTA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.33 water/powder ratio of white MTA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.40 water/powder ratio of white MTA
Number of subjects: 29
Study: 19327624

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 82

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 82
Study: 16678480

Group type: EXPERIMENTAL
Intervention: HIV uninfected children
Number of subjects: 39836

Group type: EXPERIMENTAL
Intervention: HIV infected children
Number of subjects: 39836

Group type: EXPERIMENTAL
Intervention: Children born at <36 weeks of gestational age (GA)
Number of subjects: 39836

Group type: EXPERIMENTAL
Intervention: Children born at <36 weeks of GA
Number of subjects: 39836

Group type: EXPERIMENTAL
Intervention: Children born at <32 weeks of GA
Number of subjects: 39836
Study: 15049397

Group type: EXPERIMENTAL
Intervention: Paper diary
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: IVRS diary
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both instruments
Number of subjects: 87
Study: 11370940

Group type: EXPERIMENTAL
Intervention: Beryllium Exposure Control Program including air monitoring, surface contamination controls, building design, engineering controls, worker controls, material controls, and medical surveillance.
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Area sampling concentrations
Number of subjects: 194
Study: 9260070

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 8
Study: 8320728

Group type: COMPARATOR
Intervention: 4-aminopyridine (4-AP) administered via infusion over 2 hours, with a total escalating dose from 18.0 to 33.5 mg.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle placebo administered via infusion over 2 hours.
Number of subjects: 8
Study: 3505267

Group type: EXPERIMENTAL
Intervention: Routine chest physiotherapy and suction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Suction only
Number of subjects: 20
Study: 31173921

Group type: EXPERIMENTAL
Intervention: Physical therapy informed by Acceptance and Commitment Therapy (PACT)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 248
Study: 30326045

Group type: EXPERIMENTAL
Intervention: hu3F8 (humanized anti-GD2 antibody) infused intravenously for 30 minutes on Monday, Wednesday, and Friday, with dosage escalation up to 9.6 mg/kg/cycle (approximately 288 mg/m2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor administered subcutaneously daily from 5 days before infusion through the last day of infusion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Higher dosing of hu3F8
Number of subjects: 57
Study: 27768571

Group type: EXPERIMENTAL
Intervention: Tea tree oil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyhexanide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octenidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study: 24582868

Group type: EXPERIMENTAL
Intervention: Contact lenses of +0.50 D, +2.00 D, +5.00 D, +8.00 D
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no contact lens)
Number of subjects: 6
Study: 22952551

Group type: EXPERIMENTAL
Intervention: Melatonin (3 or 6mg) combined with methylphenidate (1mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with methylphenidate (1mg/kg)
Number of subjects: 0
Study: 20557557

Group type: EXPERIMENTAL
Intervention: Spectacles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contact lenses
Number of subjects: 0
Study: 18936215

Group type: EXPERIMENTAL
Intervention: Cysteine intake of 10 mg x kg(‐1) x d(‐1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cysteine intake of 20 mg x kg(‐1) x d(‐1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cysteine intake of 30 mg x kg(‐1) x d(‐1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cysteine intake of 40 mg x kg(‐1) x d(‐1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cysteine intake of 0 mg x kg(‐1) x d(‐1)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cysteine intake (all levels)
Number of subjects: 4
Study: 15800508

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐management Program of the Stanford University
Number of subjects: 120

Group type: COMPARATOR
Intervention: 6‐month wait‐list control group
Number of subjects: 120
Study: 12578880

Group type: EXPERIMENTAL
Intervention: Intensive treatment with enalapril or nisoldipine; mean blood pressure of 128/75 mm Hg over 4 years.
Number of subjects: 950

Group type: COMPARATOR
Intervention: Moderate blood pressure control (placebo); mean blood pressure of 137/81 mm Hg over 4 years.
Number of subjects: 950
Study: 10386412

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (group IP) with two cycles of 3 min aortic cross-clamping and 2 min reperfusion before cardioplegic arrest.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (group IP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 40
Study: 8682969

Group type: EXPERIMENTAL
Intervention: 585 nm flashlamp‐pumped pulsed dye laser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (untreated scars)
Number of subjects: 22
Study: 2071809

Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises (taught and monitored for 6 months)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Phenylpropanolamine hydrochloride (50 mg a day, increasing to 50 mg twice a day)
Number of subjects: 157
Study: 6627169

Group type: EXPERIMENTAL
Intervention: Telephone reminders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mailed reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 0
Study: 28810464

Group type: EXPERIMENTAL
Intervention: Both dieted
Number of subjects: 134

Group type: COMPARATOR
Intervention: One dieted, the other ate normally
Number of subjects: 134

Group type: COMPARATOR
Intervention: Both ate normally
Number of subjects: 134
Study: 28212476

Group type: EXPERIMENTAL
Intervention: Cartilage island tympanoplasty
Number of subjects: 69

Group type: COMPARATOR
Intervention: Temporalis fascia
Number of subjects: 69
Study: 26499449

Group type: EXPERIMENTAL
Intervention: Enhanced protocol for case-finding of atrial fibrillation including pulse palpation, automated atrial fibrillation detection, and handheld single-lead ECG.
Number of subjects: 19200

Group type: EXPERIMENTAL
Intervention: Enhanced protocol for case-finding of atrial fibrillation.
Number of subjects: 19200

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 19200
Study: 23576128

Group type: COMPARATOR
Intervention: Salience network activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Default mode network recruitment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granger causality analysis
Number of subjects: 0
Study: 21161222

Group type: EXPERIMENTAL
Intervention: Fluid plus vasopressin (4 IU bolus and 2.4 IU/h infusion for 5 hours)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Fluid alone (control group)
Number of subjects: 78
Study: 19138400

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 26
Study: 18693827

Group type: EXPERIMENTAL
Intervention: Wireless devices (PDAs and tablet PCs)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Paper assessment module
Number of subjects: 79
Study: 15923572

Group type: COMPARATOR
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Etoposide, cisplatin, paclitaxel, and granulocyte colony-stimulating factor (PET)
Number of subjects: 587
Study: 12042191

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Divalproex (500-2500 mg/day in divided doses)
Number of subjects: 248
Study: 9676304

Group type: EXPERIMENTAL
Intervention: 6% Dextran (D)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Electrolyte solution (VE)
Number of subjects: 24
Study: 7786368

Group type: EXPERIMENTAL
Intervention: AOD curriculum participation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Curriculum components
Number of subjects: 25
Study: 2193836

Group type: EXPERIMENTAL
Intervention: Cefetamet 500 mg orally twice daily for 7 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cefaclor 500 mg orally three times daily for 7 days
Number of subjects: 41
Study: 351755

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenoterol (FEN)
Number of subjects: 0
Study: 31221489

Group type: EXPERIMENTAL
Intervention: Brief inpatient psychoeducational intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 121
Study: 28976431

Group type: EXPERIMENTAL
Intervention: GAP score (proportioned spinopelvic state)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Moderately disproportioned spinopelvic state
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Severely disproportioned spinopelvic state
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: GAP score
Number of subjects: 222
Study: 25789444

Group type: EXPERIMENTAL
Intervention: Water only (treatment A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Water + cola (treatment B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Water + diet cola (treatment C)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Water + cola + diet cola + orange juice (treatment D)
Number of subjects: 34
Study: 23766337

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 0
Study: 21332346

Group type: EXPERIMENTAL
Intervention: Low-dose NCTD (0.05 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose NCTD (0.1 mg/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model group (DN rats without treatment)
Number of subjects: 0
Study: 19732995

Group type: EXPERIMENTAL
Intervention: Experimental group (exposed to the reminiscence program)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo-control group (with weekly relaxation sessions)
Number of subjects: 90
Study: 17237686

Group type: EXPERIMENTAL
Intervention: Double-flap anastomosis (Group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Excision of the posterior flaps (Group B)
Number of subjects: 63
Study: 15497493

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogen (CE)/5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol/1 mg norethisterone acetate (NETA)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: estradiol/NETA
Number of subjects: 249
Study: 11521964

Group type: EXPERIMENTAL
Intervention: CLA supplementation (Tonalin capsules providing 3.9 g/d of CLA isomers)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo oil (sunflower) supplementation (6 daily capsules of 1 g each)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CLA supplementation
Number of subjects: 17
Study: 9469324

Group type: EXPERIMENTAL
Intervention: FU24h/LV
Number of subjects: 236

Group type: COMPARATOR
Intervention: FU24h/IFN
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: FU24h/LV/IFN
Number of subjects: 236
Study: 7921857

Group type: EXPERIMENTAL
Intervention: Esmolol 60 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Esmolol 40 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Esmolol 20 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline (Control Group A)
Number of subjects: 200
Study: 3377947

Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 5 mg in saline 10 ml with adrenaline 1 in 200,000
Number of subjects: 54

Group type: COMPARATOR
Intervention: Extradural diamorphine 5 mg in saline 10 ml without adrenaline (saline group)
Number of subjects: 54
Study: 5057006

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 gram per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31821698

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) intervention
Number of subjects: 37
Study: 31297513

Group type: EXPERIMENTAL
Intervention: Self-assessment using a tablet
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard assessment by a research assistant (RA)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Self-assessment using a tablet (for patients aged ≥85)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard assessment by a research assistant (RA) (for caregivers)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Self-assessment using a tablet (for caregivers)
Number of subjects: 67
Study: 29564034

Group type: EXPERIMENTAL
Intervention: Risky sexual behavior assessment among sexually active students
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression analysis
Number of subjects: 627
Study: 26252290

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane and Propofol
Number of subjects: 30
Study: 23793776

Group type: EXPERIMENTAL
Intervention: HAP imaging with 80 kVp using a 320-detector-rows ADCT scanner
Number of subjects: 128

Group type: COMPARATOR
Intervention: Routine HAP imaging with 120 kVp using 64-slice helical acquisition
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: HAP imaging with 80 kVp
Number of subjects: 128
Study: 21534836

Group type: COMPARATOR
Intervention: Multicomponent environmental intervention including employee advisory committees, point‐of‐decision prompts, walking paths, cafeteria/vending changes, and educational materials.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 8
Study: 19559166

Group type: EXPERIMENTAL
Intervention: Hypertension self-management intervention delivered by a nurse over the telephone
Number of subjects: 528

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 528
Study: 16445258

Group type: EXPERIMENTAL
Intervention: Hybrid retinal image registration approach combining area-based and feature-based methods
Number of subjects: 504
Study: 14519797

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate (400 IU/d)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 10740948

Group type: EXPERIMENTAL
Intervention: Trauma writing condition
Number of subjects: 98

Group type: COMPARATOR
Intervention: Trivial writing control
Number of subjects: 98

Group type: COMPARATOR
Intervention: No-writing control
Number of subjects: 98
Study: 8912036

Group type: EXPERIMENTAL
Intervention: Earlier age of onset of bulimia
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Lower character scores (measured by the Temperament and Character Inventory)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Worse mean parental care (from the Parental Bonding Instrument)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Absence of any lifetime anxiety disorder
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Presence of any lifetime mood disorder
Number of subjects: 114
Study: 1420749

Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algicon Suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 0
Study: 6319067

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg every 12 hr)
Number of subjects: 10
Study: 29924506

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 26842950

Group type: EXPERIMENTAL
Intervention: anakinra-methotrexate
Number of subjects: 154

Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 154
Study: 25371639

Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan
Number of subjects: 60
Study: 21907450

Group type: EXPERIMENTAL
Intervention: Curcuminoids (6000 mg/d in 3 divided doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20827138

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 7
Study: 18184542

Group type: EXPERIMENTAL
Intervention: Huannao Yicong capsule
Number of subjects: 90

Group type: COMPARATOR
Intervention: Aniracetam
Number of subjects: 90
Study: 11530030

Group type: EXPERIMENTAL
Intervention: Low-dose inhaled fluticasone (88 microg twice daily)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Oral zafirlukast (20 mg twice daily)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Switching from zafirlukast to fluticasone (88 microg twice daily)
Number of subjects: 294
Study: 9587723

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 7930305

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg three times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3371476

Group type: EXPERIMENTAL
Intervention: Nolvadex (tamoxifen)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 87
Study: 31980978

Group type: EXPERIMENTAL
Intervention: Dotinurad 2 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Benzbromarone 50 mg
Number of subjects: 201
Study: 30219400

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol before primary PCI
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 197
Study: 28599338

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (phone calls every 4 weeks over 6 months)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study: 25987198

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for panic disorder
Number of subjects: 379

Group type: COMPARATOR
Intervention: Higher aggression levels
Number of subjects: 379
Study: 24390944

Group type: EXPERIMENTAL
Intervention: Omeprazole and NAC
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omeprazole and placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: NAC and placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90